About biOasis Technologies Inc.

This author has not yet filled in any details.
So far biOasis Technologies Inc. has created 115 blog entries.
31 Mar,2017

biOasis Announces Oversubscription of Financing

By | Friday, March 31, 2017|2017 Press Releases, Corporate Press Releases|

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Download this as a PDF March 31st, 2017, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) is pleased to announce that further to its press release dated March 20, 2017, the Company’s non-brokered private placement (the "Private Placement"), is [...]

20 Mar,2017

biOasis Announces Non-Brokered Private Placement

By | Monday, March 20, 2017|2017 Press Releases, Corporate Press Releases|

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Download this as a PDF March 20th, 2017, Vancouver, BC biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) announces a nonbrokered private placement of up to 4,500,000 units at a price of $0.70 per unit of gross proceeds of up to [...]

23 Jan,2017

biOasis Provides AGM Update – Expanding The biOasis Deal Flow Pipeline

By | Monday, January 23, 2017|2017 Press Releases, Corporate Press Releases|

Download this as a PDF January 23rd, 2017, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier (BBB), has provided a corporate update in advance of its Annual and Special Meeting of Shareholders to be held at 1780 - 400 Burrard Street, [...]

23 Dec,2016

biOasis Announces Adoption of Restricted Share Unit Plan

By | Friday, December 23, 2016|2016 Press Releases, Corporate Press Releases, Uncategorized|

Download this as a PDF December 22nd, 2016, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the “Company”) announces that subject to approval by the TSX Venture Exchange ("TSXV") and ratification by the Company's shareholders at the 2016 Annual and Special General Meeting of shareholders (the "AGM"), the Company adopted a restricted share unit plan (the [...]

07 Nov,2016

biOasis Attends BIO Europe and the Lockman BT2111 Paper is Honored by being Featured on the Cover of Pharmaceutical Research’s December Journal

By | Monday, November 7, 2016|2016 Press Releases, Corporate Press Releases|

Download this as a PDF November 6th, 2016, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced it’s team is attending BIO Europe, November 7th to 9th, in Cologne, Germany. In addition, the company announced that Dr. [...]

25 Oct,2016

biOasis Engages Rising Tide Equity to Increase Global Awareness

By | Tuesday, October 25, 2016|2016 Press Releases, Corporate Press Releases|

Download this as a PDF October 23rd, 2016, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced it has engaged Rising Tide Equity to increase its global awareness. Investors are increasingly using digital media and non-traditional media [...]

27 Sep,2016

biOasis Enters Into a License Agreement With Vaccinex Inc

By | Tuesday, September 27, 2016|2016 Press Releases, Corporate Press Releases|

Download this as a PDF September 20th, 2016, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (“biOasis”), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, today announced it has entered into a License Agreement (the “Agreement”) with Vaccinex Inc. (“Vaccinex”). Under the terms of the Agreement, Vaccinex [...]

29 Aug,2016

biOasis Announces Publication of Scientific Paper – Transcend-Based Anti-Cancer Antibody BT2111 Crosses the Blood-Brain Barrier and Shows Efficacy in the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brains of Animal Model

By | Monday, August 29, 2016|2016 Press Releases, Corporate Press Releases|

Download this as a PDF August 29, 2016, Vancouver, BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), today announced the publication of a peer-reviewed scientific paper detailing the results of an in-vivo study of the treatment of Metastatic HER2+ [...]

10 Jul,2016

biOasis Announces the Issuance of an Additional US Patent for The Delivery of Therapeutic Agents Across The Blood-Brain Barrier.

By | Sunday, July 10, 2016|2016 Press Releases, Corporate Press Releases|

Download this as a PDF July 10, 2016, VANCOUVER BC BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB), announces the issuance of a US patent covering a refined subset of fragments found within Melanotransferrin or P97 for the delivery of [...]